Researchers suggest people taking Ozempic and similar drugs may face double the risk of developing wet age-related macular ...

A recent study found that older adults with diabetes who use a GLP-1 drug have double the risk of developing wet age-related ...

Ocular Therapeutix is making sure its corporate vision is 20/20 as it looks forward to phase 3 data on its eye disease drug candidate Axpaxli. | Ocular Therapeutix is making sure its corporate vision ...

Axpaxli is Ocular's main value driver, targeting a large wet AMD market with a differentiated, sustained-release TKI ...

In this video, Peter K. Kaiser, MD, founding director of the Digital Eye Optical Coherence Tomography Reading Center at the ...

The European Commission has cleared the high-strength formulation of Eylea (aflibercept) with an extended treatment interval ...

Canadian researchers find that taking semaglutide increases the chances of developing neovascular age-related macular ...

However, at the 18–30 month mark, GLP-1 users’ risk of developing wet AMD more than doubled compared to non-users. And those taking the drugs for 30 months or longer had more than triple the risk.

Market is one of the leading causes of irreversible vision loss in individuals aged 50 and above. With the global aging population increasing rapidly, the burden of AMD is escalating, pushing the ...

Canadian study reveals diabetic patients taking GLP-1 medications face twice the risk of eye problems, with longer exposure ...

Before drugs were developed to treat wet AMD, the main treatment was a procedure known as laser photocoagulation, which used a laser beam to seal leaking blood vessels. [11] ...

CHENNAI: Biocon Biologics, the biosimilars subsidiary of Biocon Ltd, said on Friday that Health Canada has granted a Notice ...